MedPath

Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)

Phase 3
Terminated
Conditions
Post-traumatic Stress Disorder
PTSD
Interventions
Drug: Placebo
Drug: Brexpiprazole
Registration Number
NCT01987960
Lead Sponsor
H. Lundbeck A/S
Brief Summary

To evaluate the efficacy of brexpiprazole as adjunctive treatment to paroxetine (PAR) or sertraline (SER) on PTSD symptoms.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
417
Inclusion Criteria
  • The patient has PTSD, diagnosed according to DSM-IV-TR™ and confirmed by the Mini International Neuropsychiatric Interview (MINI).
  • The patient has a Clinician-Administered PTSD Scale Part 2 (CAPS-2) total score ≥70 at Screening and Baseline Visits.
  • The reported duration of the PTSD is at least 3 months.
Read More
Exclusion Criteria
  • The index traumatic event that led to development of PTSD took place more than 15 years before screening.
  • The patient has a severe personality disorder that in the investigator's opinion may interfere with the conduct of the study.
  • The patient is at significant suicidal risk.

Other inclusion and exclusion criteria may apply.

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboPlacebo adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER)
BrexpiprazoleBrexpiprazoleBrexpiprazole adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER). Brexpiprazole dosing was 1mg/day for one week, followed by 2mg/day for 3 weeks. Thereafter the dose was flexible and could be adjusted from 1 to 3 mg/day.
Primary Outcome Measures
NameTimeMethod
PTSD Symptoms Using CAPS-2 Total ScorePeriod 2: Baseline to Week 12 (of randomized period)

Clinician-Administered PTSD Scale Part 2 (CAPS-2): 17 items in criteria B, C and D (Corresponding to CAPS-2) will be administered to provide a total score. They are rated on a 5 point scale for frequency from 0 (never or none) to 4 (daily or almost every day), and intensity from 0 (none) to 4 (extreme). The sum of the 17 items gives a toal score ranging from 0 to 136, with a higher score indicating greater symptom severity.

Secondary Outcome Measures
NameTimeMethod
Global Clinical Impression Severity of Illness (CGI-S) ScorePeriod 2: Baseline to Week 12 (of randomized period)

Clinical Global Impression - Severity of Illness (CGI-S) The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).

Trial Locations

Locations (59)

PL002

🇵🇱

Lublin, Poland

FI004

🇫🇮

Turku, Finland

FI002

🇫🇮

Helsinki, Finland

IT002

🇮🇹

Siena, Italy

US003

🇺🇸

Austin, Texas, United States

FI003

🇫🇮

Helsinki, Finland

FI005

🇫🇮

Tampere, Finland

FR001

🇫🇷

Tours Cedex 9, France

PL005

🇵🇱

Gdansk, Poland

PL003

🇵🇱

Bialystok, Poland

PL001

🇵🇱

Leszno, Poland

US016

🇺🇸

Jacksonville, Florida, United States

US014

🇺🇸

Norristown, Pennsylvania, United States

RS005

🇷🇸

Novi Knezevac, Serbia

ZA003

🇿🇦

Cape Town, South Africa

RS004

🇷🇸

Nis, Serbia

ZA006

🇿🇦

Bloemfontein, South Africa

US021

🇺🇸

Roslindale, Massachusetts, United States

SE002

🇸🇪

Stockholm, Sweden

ZA007

🇿🇦

Port Elizabeth, South Africa

FI001

🇫🇮

Kuopio, Finland

FI006

🇫🇮

Oulu, Finland

FR003

🇫🇷

Laxou, France

US011

🇺🇸

Memphis, Tennessee, United States

EE001

🇪🇪

Tallinn, Estonia

IT005

🇮🇹

Andria, Italy

IT003

🇮🇹

Lecce, Italy

IT001

🇮🇹

Pisa, Italy

SE003

🇸🇪

Uppsala, Sweden

FR002

🇫🇷

Fort de France, France

FR005

🇫🇷

Thuir Cedex, France

ZA004

🇿🇦

Cape Town, South Africa

US017

🇺🇸

Tampa, Florida, United States

US001

🇺🇸

Bronx, New York, United States

US005

🇺🇸

Dayton, Ohio, United States

IT004

🇮🇹

Catania, Italy

US007

🇺🇸

Nashua, New Hampshire, United States

US020

🇺🇸

North Miami, Florida, United States

FR004

🇫🇷

Nimes Cedex 9, France

RS006

🇷🇸

Belgrade, Serbia

ZA002

🇿🇦

Cape Town, South Africa

ZA001

🇿🇦

Pretoria, South Africa

ZA005

🇿🇦

Cape Town, South Africa

ZA008

🇿🇦

Durban, South Africa

SE001

🇸🇪

Falun, Sweden

ZA009

🇿🇦

Pretoria, South Africa

PL004

🇵🇱

Gdansk, Poland

US004

🇺🇸

Los Angeles, California, United States

US002

🇺🇸

Bradenton, Florida, United States

US006

🇺🇸

Gainesville, Florida, United States

US025

🇺🇸

Los Angeles, California, United States

US024

🇺🇸

Riverside, California, United States

US015

🇺🇸

San Diego, California, United States

US008

🇺🇸

San Diego, California, United States

US012

🇺🇸

Indianapolis, Indiana, United States

US019

🇺🇸

Las Vegas, Nevada, United States

US009

🇺🇸

Cincinnati, Ohio, United States

US010

🇺🇸

Portland, Oregon, United States

US026

🇺🇸

Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath